Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment (original) (raw)
Aebi H (1974) Catalase. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Academic Press, New York and London, pp 73–77
Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Antioxidant enzyme and malondialdehyde levels in patients with social phobia. Psychiatry Res (in press)
Baumann P, Rochat B (1995) Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10:15–21 Google Scholar
Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64:43–51 CASPubMed Google Scholar
Bouwer C, Stein DJ (1998) Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 49:79–82 ArticleCASPubMed Google Scholar
Britt SG, Chiu VW, Redpath GT, Vandenberg SR (1992) Elimination of ascorbic acid-induced membrane lipid peroxidation and serotonin receptor loss by Trolox-C, a water soluble analogue of vitamin E. J Recept Res 12:181–200 CASPubMed Google Scholar
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome-P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262–265 CASPubMed Google Scholar
Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U (1995) Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine: a double- blind placebo-controlled study. Acta Psychiatr Scand 92:351–358 CASPubMed Google Scholar
Gelertner CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatment of social phobia. Arch Gen Psychiatry 48: 938–945 PubMed Google Scholar
Gergel I, Pitts C, Oakes R, Kumar R (1997) Significant improvement in symptoms of social phobia after paroxetine treatment. Biol Psychiatry 42:12–14 Google Scholar
Glue P, Banfield C (1996) Psychiatry, psychopharmacology and P450s. Human Psychopharmacol 11:97–114 ArticleCAS Google Scholar
Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633–643 CASPubMed Google Scholar
Gutteridge JMC (1995) Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 41:1819–1828 CASPubMed Google Scholar
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62 CASPubMed Google Scholar
Herken H, Uz E, Özyurt H, Soğut S, Virit O, Akyol O (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6:66–73 ArticleCASPubMed Google Scholar
Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC (1995) Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 152: 1368–1371 CASPubMed Google Scholar
Kuloglu M, Atmaca M, Tezcan E, Gecici O, Tunckol H, Ustundag B (2002a) Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive compulsive disorder. Neuropsychobiology 46:27–32 ArticleCAS Google Scholar
Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan E, Cinkilinc N (2002b) Lipid peroxidation and antioxidant enzyme levels of patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171–175 CAS Google Scholar
Liebowitz MR (1987) Social phobia. Mod Probl Pharmacopsychiatr 33:141–173 Google Scholar
Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF (1992) Phenelzine vs. atenolol in social phobia. Arch Gen Psychiatry 49:290–300 CASPubMed Google Scholar
Lohr JB (1991) Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry 48:1097–1106 CASPubMed Google Scholar
Maes M, Vandooaeghe E, Van Hunsel F, Bril T, Demedts P, Wautres A, Neels H (1997) Immune disturbances in treatment-resistant depression, modulation by antidepressive treatments. Human Psychopharmacol 12:153–162 CAS Google Scholar
Maes M, Christophe A, Delange J, Neels H, Scharpe S, Meltzer HY (1999) Lowered omega 3 polyunsaturated fatty acids in serum phospholipids and cholesterol esters of depressed patients. Psychiatry Res 85:275–291 CASPubMed Google Scholar
Mahadik SP, Mukherjee S (1996) Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 19:1–17 ArticleCASPubMed Google Scholar
Montgomery SA, Pitts C, Oakes R, Hunter B, Gergel I (1998) Paroxetine in severe social phobia. Eur Psychiatry 13(Suppl. 4):237S–238S Article Google Scholar
Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158–168 CASPubMed Google Scholar
Pandey GN, Sharma RP, Janicak PG, Davis JM (1992) Monoamine oxidase and cortisol response in depression and schizophrenia. Psychiatry Res 44:198 Article Google Scholar
Ravindran AV, Griffiths J, Merali Z, Anisman H (1995) Lymphocyte subsets associated with major depression and dysthymia, modification by antidepressant treatment. Psychosom Med 57:555–563 CASPubMed Google Scholar
Satoh K (1978) Serum lipoperoxides in cerebrovascular disorders determined by colorimetric method. Clin Chim Acta 90:37–43 ArticleCASPubMed Google Scholar
Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF, Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:11–17 CASPubMed Google Scholar
Skjelbo E, Brøsen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34:256–261 CASPubMed Google Scholar
Spitzer RL, Williams JBW, Gibbon M, First M (1990) Structured Interview for DSM-III-R, Nonpatient Version (SCID-NP, Version 1.0). American Psychiatric Press, Washington, DC
Spitzer RL, Williams JBW, Gibbon M, First M (1987) Structured Interview for DSM-III-R (SCID). New York State Psychiatric Institute, New York, Biometrics Research
Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34:497–500 CASPubMed Google Scholar
Van der Linden G, Van Heerden B, Warwick J, Wessels J, Van Kradenburg J, Zungu-Dirwayi N, Stein DJ (2000) Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 24:419–438 ArticleCASPubMed Google Scholar
Van der Vliet A, Bast A (1992) Effect of oxidative stress on receptors and signal transmission. Chem Biol Interact 85:95–116 ArticleCASPubMed Google Scholar
Van Vliet IM, den Boer JA, Westenberg HG (1994) Psychopharmacological treatment of social phobia: a double-blind, placebocontrolled study with fluvoxamine. Psychopharmacology 115: 128–134 CASPubMed Google Scholar
Versiani M, Nardi AE, Mindim FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353–360 CASPubMed Google Scholar
Yagi K (1984) Assay for plasma lipid peroxides. Methods Enzymol 109:328–331 Google Scholar
Yao JK, Reddy R, van Kammen DP (1998) Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80:29–39 ArticleCASPubMed Google Scholar